Baker E H, Janaway C H, Philips B J, Brennan A L, Baines D L, Wood D M, Jones P W
Glucose and Pulmonary Infection Group, Cardiac and Vascular Sciences (Respiratory), St George's, University of London, Cranmer Terrace, London SW17 0RE, UK.
Thorax. 2006 Apr;61(4):284-9. doi: 10.1136/thx.2005.051029. Epub 2006 Jan 31.
Hyperglycaemia is associated with poor outcomes from pneumonia, myocardial infarction and stroke, but the effect of blood glucose on outcomes from acute exacerbations of chronic obstructive pulmonary disease (AECOPD) has not been established. Recent UK guidelines do not comment on measurement or control of blood glucose in AECOPD. A study was therefore undertaken to determine the relationship between blood glucose concentrations, length of stay in hospital, and mortality in patients admitted with AECOPD.
Data were retrieved from electronic records for patients admitted with AECOPD with lower respiratory tract infection in 2001-2. The patients were grouped according to blood glucose quartile (group 1, <6 mmol/l (n = 69); group 2, 6.0-6.9 mmol/l (n = 69); group 3, 7.0-8.9 mmol/l (n = 75); and group 4, >9.0 mmol/l (n = 71)).
The relative risk (RR) of death or long inpatient stay was significantly increased in group 3 (RR 1.46, 95% CI 1.05 to 2.02, p = 0.02) and group 4 (RR 1.97, 95% CI 1.33 to 2.92, p < 0.0001) compared with group 1. For each 1 mmol/l increase in blood glucose the absolute risk of adverse outcomes increased by 15% (95% CI 4 to 27), p = 0.006. The risk of adverse outcomes increased with increasing hyperglycaemia independent of age, sex, a previous diagnosis of diabetes, and COPD severity. Isolation of multiple pathogens and Staphylococcus aureus from sputum also increased with increasing blood glucose.
Increasing blood glucose concentrations are associated with adverse clinical outcomes in patients with AECOPD. Tight control of blood glucose reduces mortality in patients in intensive care or following myocardial infarction. A prospective study is now required to determine whether control of blood glucose can also improve outcomes from AECOPD.
高血糖与肺炎、心肌梗死及中风的不良预后相关,但血糖对慢性阻塞性肺疾病急性加重期(AECOPD)预后的影响尚未明确。英国近期的指南未对AECOPD患者血糖的测量或控制作出评论。因此开展了一项研究,以确定AECOPD入院患者的血糖浓度、住院时间及死亡率之间的关系。
从2001 - 2002年因下呼吸道感染而入院的AECOPD患者的电子记录中检索数据。患者根据血糖四分位数分组(第1组,<6 mmol/L(n = 69);第2组,6.0 - 6.9 mmol/L(n = 69);第3组,7.0 - 8.9 mmol/L(n = 75);第4组,>9.0 mmol/L(n = 71))。
与第1组相比,第3组(相对风险(RR)1.46,95%可信区间1.05至2.02,p = 0.02)和第4组(RR 1.97,95%可信区间1.33至2.92,p < 0.0001)死亡或住院时间长的相对风险显著增加。血糖每升高1 mmol/L,不良结局的绝对风险增加15%(95%可信区间4至27),p = 0.006。不良结局风险随高血糖程度加重而增加,且与年龄、性别、既往糖尿病诊断及慢性阻塞性肺疾病严重程度无关。痰液中分离出多种病原体及金黄色葡萄球菌的情况也随血糖升高而增加。
AECOPD患者血糖浓度升高与不良临床结局相关。严格控制血糖可降低重症监护患者或心肌梗死后患者的死亡率。现在需要进行一项前瞻性研究,以确定控制血糖是否也能改善AECOPD的预后。